NCT07616635已完成3 期
Fosfomycin Versus Ciprofloxacin for Febrile Neutropenia Prophylaxis in High-risk Haematological Patients (FOVOCIP): a Phase 3, Open-label, Multicentre, Randomised, Non-inferiority Trial.
Fundación para la Investigación Biosanitaria del Principado de Asturias1 个研究点 分布在 1 个国家目标入组 177 人开始时间: 2022年3月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 177
- 试验地点
- 1
研究概览
简要总结
Prophylaxis with fluoroquinolones in high-risk neutropenic patients is currently under scrutiny due to their toxicity and the potential of selecting multirresistant bacteria. In this setting, the search for an alternative prophylactic drug is a priority. The FOVOCIP study aimed to evaluate the efficacy and safety of fosfomycin compared to ciprofloxacin in this population. This was a multicentre, randomised, phase-3, non-inferiority, open-label trial performed in 11 centres in Spain. Adults diagnosed with acute leukaemia or recipients of a Haematopoietic Stem Cell Transplant were randomised to receive oral fosfomycin or oral ciprofloxacin as prophylaxis. The primary endpoint was rate of febrile neutropenia. Secondary endpoints included safety, including microbiological safety and gut microbiota changes .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be able to understand the study procedures, comply with them, and provide written informed consent prior to any specific study procedures.
- •Adult subjects ≥ 18 years of age diagnosed with acute leukaemia who are scheduled to receive a first course of intensive chemotherapy.
- •Adult subjects ≥ 18 years of age who are candidates for a first allogeneic haematopoietic stem cell transplant with myeloablative conditioning or adult subjects ≥ 18 years of age who are candidates for a first allogeneic haematopoietic stem cell transplant with reduced-intensity conditioning or an autologous haematopoietic stem cell transplant, provided that at least one of the following risk factors for infection is present:
- •Functional status (Eastern Cooperative Oncology Group, ECOG) ≥
- •Expected grade 3-4 mucositis.
- •Age ≥65 years.
- •Comorbidity index (HCTI) ≥
- •Serum albumin < 35 g/L.
- •Active or refractory neoplasia at the time of stem cell transplantation.
- •Total dose of etoposide > 500 mg/m
- •Total dose of cytarabine > 1 g/m
- •Functional status (Eastern Cooperative Oncology Group, ECOG) from 0 to
- •Adequate organ function defined as:
- •Liver: bilirubin, alkaline phosphatase or SGOT < 3 times the upper normal limit (unless attributable to tumour activity).
- •Renal: creatinine ≤ 250 μmol/l (2.5 mg/dL) (unless attributable to leukemic infiltration).
- •Life expectancy greater than 3 months.
- •Women of childbearing age must not be pregnant or breastfeeding and must have a negative pregnancy test at the time of screening. Women of childbearing age and men with female partners of childbearing age must commit to using two highly effective forms of contraception and must agree not to become pregnant or father a child while receiving any study therapy and for at least 3 months after completing treatment.
排除标准
- •Patients who meet any of the following exclusion criteria will not be eligible for inclusion in this study:
- •Hypersensitivity to fluoroquinolones or fosfomycin.
- •Treatment with broad-spectrum antimicrobial therapy within 4 weeks of the first study treatment.
- •Intensive chemotherapy or previous haematopoietic stem cell transplantation. Treatment with hydroxyurea or corticosteroids used to control white blood cell count is permitted.
- •Fever of infectious origin or documented infection within 4 weeks of the first study treatment.
- •Presence of any serious psychiatric illness or physical condition that, in the opinion of the physicians, contraindicates the patient's inclusion in the clinical trial.
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
A study to find out if giving levofloxacin prevents infections in children and teenagers (1 to 18 years) receiving treatment for blood cancers (leukemia and lymphoma)CTRI/2025/09/095414AIIMS Bhopal102
尚未招募
不适用
Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile NeutropeniaNCT07277387Instituto de Investigación Biomédica de Salamanca350
尚未招募
不适用
Checking the difference in usefulness and cost of two ways of giving meropenem medicine to cancer child patients with fever and low immunityCTRI/2025/10/096008Dr M S Ganachari80
尚未招募
不适用
Implementing an empirical antibiotic discontinuation strategyCTRI/2024/09/074088JIPMER30
招募中
不适用
Antibiotic Duration and Outcomes in High-Risk Febrile Neutropenia PatientsNCT07372131Valeria Cento172